is bpc 157 intramuscular or subcutaneous bpc-157 clinical trials dosage BPC-157 Dosing (Common Protocols), πΉ Oral / Subcutaneous, β’ 500 mcg daily, β’ Duration: 6 weeks, πΉ / Peritendinous, β’ 1 mg daily, β’ Duration: 6 weeks, β οΈ Note:, Not approved by FDA bpc-157 injection subcutaneous vs intramuscular
Description
The substance appears on the prohibited list under substances without current approval for human therapeutic use
Symptoms often include fatigue, lightheadedness, pale skin, shortness of breath, and cognitive fog
Vegetarians and Stroke Risk FactorsVitamin B12 and Homocysteine
J Physiol Paris 93(6):505512 Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V, et al (1997) Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats
So for people that suffer from IBS, irritable bowel syndrome, or from colitis, or from other gut issues, There is a potential use for therapeutic peptides
See the lab reports Bacteriostatic water dissolves the lyophilized powder
